Global Test Phantoms
Global Test Phantoms

Test Phantoms Comprehensive Study by Type (CT Test Phantoms, Mammography Test Phantoms, Ultrasound Test Phantoms, Radiation Oncology Test Phantoms, MRI Test Phantoms, Others), Application (Research institute, School, Hospital, Others), Patient Type (Adult, Pediatric), Technologies (Radioactive spheres, Radiography, MRI versions, Others) Players and Region - Global Market Outlook to 2025

Test Phantoms Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Sep 2020 Edition 207 Pages 220 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study



The market study is being classified by Type (CT Test Phantoms, Mammography Test Phantoms, Ultrasound Test Phantoms, Radiation Oncology Test Phantoms, MRI Test Phantoms and Others), by Application (Research institute, School, Hospital and Others) and major geographies with country level break-up.

Gammex (United States), Fluke (United States), Standard Imaging (United States), Biodex Medical Systems (United States), RaySafe (Sweden), Capintec (United States), Pro-Project (Poland), The Phantom Laboratory (United States), Radiology Support Devices (United States) and Modus Medical Devices (Canada) are some of the key players profiled in the study.

The global Test Phantoms market is fragmented due to the presence of regional and global manufacturers. The level of competition among the companies in the Test Phantoms market is intense and manufacturers focus on developing new technologies and offering customized products to the customers. In the coming years, manufacturers will also develop new partnerships to spread their product reach to more customers globally. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Test Phantoms market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Test Phantoms market by Type, Application and Region.

On the basis of geography, the market of Test Phantoms has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing the use of imaging techniques in the healthcare sector
  • Increasing prevalence of various chronic


Restraints
  • high maintenance cost associated

Opportunities
  • The growing prevalence of various chronic diseases such as HIV, tuberculosis, and cancer is expected to contribute to the opportunities of growth of the Test Phantoms

Challenges
  • Key competition between manufacturers





Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Test Phantoms Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms and Government Regulatory and Research Organizations

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • CT Test Phantoms
  • Mammography Test Phantoms
  • Ultrasound Test Phantoms
  • Radiation Oncology Test Phantoms
  • MRI Test Phantoms
  • Others
By Application
  • Research institute
  • School
  • Hospital
  • Others
By Patient Type
  • Adult
  • Pediatric

By Technologies
  • Radioactive spheres
  • Radiography
  • MRI versions
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing the use of imaging techniques in the healthcare sector
      • 3.2.2. Increasing prevalence of various chronic
    • 3.3. Market Challenges
      • 3.3.1. Key competition between manufacturers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Test Phantoms, by Type, Application, Patient Type, Technologies and Region (value, volume and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Test Phantoms (Value)
      • 5.2.1. Global Test Phantoms by: Type (Value)
        • 5.2.1.1. CT Test Phantoms
        • 5.2.1.2. Mammography Test Phantoms
        • 5.2.1.3. Ultrasound Test Phantoms
        • 5.2.1.4. Radiation Oncology Test Phantoms
        • 5.2.1.5. MRI Test Phantoms
        • 5.2.1.6. Others
      • 5.2.2. Global Test Phantoms by: Application (Value)
        • 5.2.2.1. Research institute
        • 5.2.2.2. School
        • 5.2.2.3. Hospital
        • 5.2.2.4. Others
      • 5.2.3. Global Test Phantoms by: Patient Type (Value)
        • 5.2.3.1. Adult
        • 5.2.3.2. Pediatric
      • 5.2.4. Global Test Phantoms by: Technologies (Value)
        • 5.2.4.1. Radioactive spheres
        • 5.2.4.2. Radiography
        • 5.2.4.3. MRI versions
        • 5.2.4.4. Others
      • 5.2.5. Global Test Phantoms Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Test Phantoms (Volume)
      • 5.3.1. Global Test Phantoms by: Type (Volume)
        • 5.3.1.1. CT Test Phantoms
        • 5.3.1.2. Mammography Test Phantoms
        • 5.3.1.3. Ultrasound Test Phantoms
        • 5.3.1.4. Radiation Oncology Test Phantoms
        • 5.3.1.5. MRI Test Phantoms
        • 5.3.1.6. Others
      • 5.3.2. Global Test Phantoms by: Application (Volume)
        • 5.3.2.1. Research institute
        • 5.3.2.2. School
        • 5.3.2.3. Hospital
        • 5.3.2.4. Others
      • 5.3.3. Global Test Phantoms by: Patient Type (Volume)
        • 5.3.3.1. Adult
        • 5.3.3.2. Pediatric
      • 5.3.4. Global Test Phantoms by: Technologies (Volume)
        • 5.3.4.1. Radioactive spheres
        • 5.3.4.2. Radiography
        • 5.3.4.3. MRI versions
        • 5.3.4.4. Others
      • 5.3.5. Global Test Phantoms Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Test Phantoms (Price)
      • 5.4.1. Global Test Phantoms by: Type (Price)
  • 6. Test Phantoms: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Gammex (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Fluke (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Standard Imaging (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Biodex Medical Systems (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. RaySafe (Sweden)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Capintec (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pro-Project (Poland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. The Phantom Laboratory (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Radiology Support Devices (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Modus Medical Devices (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Test Phantoms Sale, by Type, Application, Patient Type, Technologies and Region (value, volume and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Test Phantoms (Value)
      • 7.2.1. Global Test Phantoms by: Type (Value)
        • 7.2.1.1. CT Test Phantoms
        • 7.2.1.2. Mammography Test Phantoms
        • 7.2.1.3. Ultrasound Test Phantoms
        • 7.2.1.4. Radiation Oncology Test Phantoms
        • 7.2.1.5. MRI Test Phantoms
        • 7.2.1.6. Others
      • 7.2.2. Global Test Phantoms by: Application (Value)
        • 7.2.2.1. Research institute
        • 7.2.2.2. School
        • 7.2.2.3. Hospital
        • 7.2.2.4. Others
      • 7.2.3. Global Test Phantoms by: Patient Type (Value)
        • 7.2.3.1. Adult
        • 7.2.3.2. Pediatric
      • 7.2.4. Global Test Phantoms by: Technologies (Value)
        • 7.2.4.1. Radioactive spheres
        • 7.2.4.2. Radiography
        • 7.2.4.3. MRI versions
        • 7.2.4.4. Others
      • 7.2.5. Global Test Phantoms Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Test Phantoms (Volume)
      • 7.3.1. Global Test Phantoms by: Type (Volume)
        • 7.3.1.1. CT Test Phantoms
        • 7.3.1.2. Mammography Test Phantoms
        • 7.3.1.3. Ultrasound Test Phantoms
        • 7.3.1.4. Radiation Oncology Test Phantoms
        • 7.3.1.5. MRI Test Phantoms
        • 7.3.1.6. Others
      • 7.3.2. Global Test Phantoms by: Application (Volume)
        • 7.3.2.1. Research institute
        • 7.3.2.2. School
        • 7.3.2.3. Hospital
        • 7.3.2.4. Others
      • 7.3.3. Global Test Phantoms by: Patient Type (Volume)
        • 7.3.3.1. Adult
        • 7.3.3.2. Pediatric
      • 7.3.4. Global Test Phantoms by: Technologies (Volume)
        • 7.3.4.1. Radioactive spheres
        • 7.3.4.2. Radiography
        • 7.3.4.3. MRI versions
        • 7.3.4.4. Others
      • 7.3.5. Global Test Phantoms Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Test Phantoms (Price)
      • 7.4.1. Global Test Phantoms by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Test Phantoms: by Type(USD Million)
  • Table 2. Test Phantoms CT Test Phantoms , by Region USD Million (2014-2019)
  • Table 3. Test Phantoms Mammography Test Phantoms , by Region USD Million (2014-2019)
  • Table 4. Test Phantoms Ultrasound Test Phantoms , by Region USD Million (2014-2019)
  • Table 5. Test Phantoms Radiation Oncology Test Phantoms , by Region USD Million (2014-2019)
  • Table 6. Test Phantoms MRI Test Phantoms , by Region USD Million (2014-2019)
  • Table 7. Test Phantoms Others , by Region USD Million (2014-2019)
  • Table 8. Test Phantoms: by Application(USD Million)
  • Table 9. Test Phantoms Research institute , by Region USD Million (2014-2019)
  • Table 10. Test Phantoms School , by Region USD Million (2014-2019)
  • Table 11. Test Phantoms Hospital , by Region USD Million (2014-2019)
  • Table 12. Test Phantoms Others , by Region USD Million (2014-2019)
  • Table 13. Test Phantoms: by Patient Type(USD Million)
  • Table 14. Test Phantoms Adult , by Region USD Million (2014-2019)
  • Table 15. Test Phantoms Pediatric , by Region USD Million (2014-2019)
  • Table 16. Test Phantoms: by Technologies(USD Million)
  • Table 17. Test Phantoms Radioactive spheres , by Region USD Million (2014-2019)
  • Table 18. Test Phantoms Radiography , by Region USD Million (2014-2019)
  • Table 19. Test Phantoms MRI versions , by Region USD Million (2014-2019)
  • Table 20. Test Phantoms Others , by Region USD Million (2014-2019)
  • Table 21. South America Test Phantoms, by Country USD Million (2014-2019)
  • Table 22. South America Test Phantoms, by Type USD Million (2014-2019)
  • Table 23. South America Test Phantoms, by Application USD Million (2014-2019)
  • Table 24. South America Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 25. South America Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 26. Brazil Test Phantoms, by Type USD Million (2014-2019)
  • Table 27. Brazil Test Phantoms, by Application USD Million (2014-2019)
  • Table 28. Brazil Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 29. Brazil Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 30. Argentina Test Phantoms, by Type USD Million (2014-2019)
  • Table 31. Argentina Test Phantoms, by Application USD Million (2014-2019)
  • Table 32. Argentina Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 33. Argentina Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 34. Rest of South America Test Phantoms, by Type USD Million (2014-2019)
  • Table 35. Rest of South America Test Phantoms, by Application USD Million (2014-2019)
  • Table 36. Rest of South America Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 37. Rest of South America Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 38. Asia Pacific Test Phantoms, by Country USD Million (2014-2019)
  • Table 39. Asia Pacific Test Phantoms, by Type USD Million (2014-2019)
  • Table 40. Asia Pacific Test Phantoms, by Application USD Million (2014-2019)
  • Table 41. Asia Pacific Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 42. Asia Pacific Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 43. China Test Phantoms, by Type USD Million (2014-2019)
  • Table 44. China Test Phantoms, by Application USD Million (2014-2019)
  • Table 45. China Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 46. China Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 47. Japan Test Phantoms, by Type USD Million (2014-2019)
  • Table 48. Japan Test Phantoms, by Application USD Million (2014-2019)
  • Table 49. Japan Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 50. Japan Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 51. India Test Phantoms, by Type USD Million (2014-2019)
  • Table 52. India Test Phantoms, by Application USD Million (2014-2019)
  • Table 53. India Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 54. India Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 55. South Korea Test Phantoms, by Type USD Million (2014-2019)
  • Table 56. South Korea Test Phantoms, by Application USD Million (2014-2019)
  • Table 57. South Korea Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 58. South Korea Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 59. Taiwan Test Phantoms, by Type USD Million (2014-2019)
  • Table 60. Taiwan Test Phantoms, by Application USD Million (2014-2019)
  • Table 61. Taiwan Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 62. Taiwan Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 63. Australia Test Phantoms, by Type USD Million (2014-2019)
  • Table 64. Australia Test Phantoms, by Application USD Million (2014-2019)
  • Table 65. Australia Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 66. Australia Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 67. Rest of Asia-Pacific Test Phantoms, by Type USD Million (2014-2019)
  • Table 68. Rest of Asia-Pacific Test Phantoms, by Application USD Million (2014-2019)
  • Table 69. Rest of Asia-Pacific Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 70. Rest of Asia-Pacific Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 71. Europe Test Phantoms, by Country USD Million (2014-2019)
  • Table 72. Europe Test Phantoms, by Type USD Million (2014-2019)
  • Table 73. Europe Test Phantoms, by Application USD Million (2014-2019)
  • Table 74. Europe Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 75. Europe Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 76. Germany Test Phantoms, by Type USD Million (2014-2019)
  • Table 77. Germany Test Phantoms, by Application USD Million (2014-2019)
  • Table 78. Germany Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 79. Germany Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 80. France Test Phantoms, by Type USD Million (2014-2019)
  • Table 81. France Test Phantoms, by Application USD Million (2014-2019)
  • Table 82. France Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 83. France Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 84. Italy Test Phantoms, by Type USD Million (2014-2019)
  • Table 85. Italy Test Phantoms, by Application USD Million (2014-2019)
  • Table 86. Italy Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 87. Italy Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 88. United Kingdom Test Phantoms, by Type USD Million (2014-2019)
  • Table 89. United Kingdom Test Phantoms, by Application USD Million (2014-2019)
  • Table 90. United Kingdom Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 91. United Kingdom Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 92. Netherlands Test Phantoms, by Type USD Million (2014-2019)
  • Table 93. Netherlands Test Phantoms, by Application USD Million (2014-2019)
  • Table 94. Netherlands Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 95. Netherlands Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 96. Rest of Europe Test Phantoms, by Type USD Million (2014-2019)
  • Table 97. Rest of Europe Test Phantoms, by Application USD Million (2014-2019)
  • Table 98. Rest of Europe Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 99. Rest of Europe Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 100. MEA Test Phantoms, by Country USD Million (2014-2019)
  • Table 101. MEA Test Phantoms, by Type USD Million (2014-2019)
  • Table 102. MEA Test Phantoms, by Application USD Million (2014-2019)
  • Table 103. MEA Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 104. MEA Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 105. Middle East Test Phantoms, by Type USD Million (2014-2019)
  • Table 106. Middle East Test Phantoms, by Application USD Million (2014-2019)
  • Table 107. Middle East Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 108. Middle East Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 109. Africa Test Phantoms, by Type USD Million (2014-2019)
  • Table 110. Africa Test Phantoms, by Application USD Million (2014-2019)
  • Table 111. Africa Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 112. Africa Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 113. North America Test Phantoms, by Country USD Million (2014-2019)
  • Table 114. North America Test Phantoms, by Type USD Million (2014-2019)
  • Table 115. North America Test Phantoms, by Application USD Million (2014-2019)
  • Table 116. North America Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 117. North America Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 118. United States Test Phantoms, by Type USD Million (2014-2019)
  • Table 119. United States Test Phantoms, by Application USD Million (2014-2019)
  • Table 120. United States Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 121. United States Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 122. Canada Test Phantoms, by Type USD Million (2014-2019)
  • Table 123. Canada Test Phantoms, by Application USD Million (2014-2019)
  • Table 124. Canada Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 125. Canada Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 126. Mexico Test Phantoms, by Type USD Million (2014-2019)
  • Table 127. Mexico Test Phantoms, by Application USD Million (2014-2019)
  • Table 128. Mexico Test Phantoms, by Patient Type USD Million (2014-2019)
  • Table 129. Mexico Test Phantoms, by Technologies USD Million (2014-2019)
  • Table 130. Test Phantoms Sales: by Type(K Units)
  • Table 131. Test Phantoms Sales CT Test Phantoms , by Region K Units (2014-2019)
  • Table 132. Test Phantoms Sales Mammography Test Phantoms , by Region K Units (2014-2019)
  • Table 133. Test Phantoms Sales Ultrasound Test Phantoms , by Region K Units (2014-2019)
  • Table 134. Test Phantoms Sales Radiation Oncology Test Phantoms , by Region K Units (2014-2019)
  • Table 135. Test Phantoms Sales MRI Test Phantoms , by Region K Units (2014-2019)
  • Table 136. Test Phantoms Sales Others , by Region K Units (2014-2019)
  • Table 137. Test Phantoms Sales: by Application(K Units)
  • Table 138. Test Phantoms Sales Research institute , by Region K Units (2014-2019)
  • Table 139. Test Phantoms Sales School , by Region K Units (2014-2019)
  • Table 140. Test Phantoms Sales Hospital , by Region K Units (2014-2019)
  • Table 141. Test Phantoms Sales Others , by Region K Units (2014-2019)
  • Table 142. Test Phantoms Sales: by Patient Type(K Units)
  • Table 143. Test Phantoms Sales Adult , by Region K Units (2014-2019)
  • Table 144. Test Phantoms Sales Pediatric , by Region K Units (2014-2019)
  • Table 145. Test Phantoms Sales: by Technologies(K Units)
  • Table 146. Test Phantoms Sales Radioactive spheres , by Region K Units (2014-2019)
  • Table 147. Test Phantoms Sales Radiography , by Region K Units (2014-2019)
  • Table 148. Test Phantoms Sales MRI versions , by Region K Units (2014-2019)
  • Table 149. Test Phantoms Sales Others , by Region K Units (2014-2019)
  • Table 150. South America Test Phantoms Sales, by Country K Units (2014-2019)
  • Table 151. South America Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 152. South America Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 153. South America Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 154. South America Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 155. Brazil Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 156. Brazil Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 157. Brazil Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 158. Brazil Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 159. Argentina Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 160. Argentina Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 161. Argentina Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 162. Argentina Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 163. Rest of South America Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 164. Rest of South America Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 165. Rest of South America Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 166. Rest of South America Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 167. Asia Pacific Test Phantoms Sales, by Country K Units (2014-2019)
  • Table 168. Asia Pacific Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 169. Asia Pacific Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 170. Asia Pacific Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 171. Asia Pacific Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 172. China Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 173. China Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 174. China Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 175. China Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 176. Japan Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 177. Japan Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 178. Japan Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 179. Japan Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 180. India Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 181. India Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 182. India Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 183. India Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 184. South Korea Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 185. South Korea Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 186. South Korea Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 187. South Korea Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 188. Taiwan Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 189. Taiwan Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 190. Taiwan Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 191. Taiwan Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 192. Australia Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 193. Australia Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 194. Australia Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 195. Australia Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 196. Rest of Asia-Pacific Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 197. Rest of Asia-Pacific Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 198. Rest of Asia-Pacific Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 199. Rest of Asia-Pacific Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 200. Europe Test Phantoms Sales, by Country K Units (2014-2019)
  • Table 201. Europe Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 202. Europe Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 203. Europe Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 204. Europe Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 205. Germany Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 206. Germany Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 207. Germany Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 208. Germany Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 209. France Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 210. France Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 211. France Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 212. France Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 213. Italy Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 214. Italy Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 215. Italy Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 216. Italy Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 217. United Kingdom Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 218. United Kingdom Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 219. United Kingdom Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 220. United Kingdom Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 221. Netherlands Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 222. Netherlands Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 223. Netherlands Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 224. Netherlands Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 225. Rest of Europe Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 226. Rest of Europe Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 227. Rest of Europe Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 228. Rest of Europe Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 229. MEA Test Phantoms Sales, by Country K Units (2014-2019)
  • Table 230. MEA Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 231. MEA Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 232. MEA Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 233. MEA Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 234. Middle East Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 235. Middle East Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 236. Middle East Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 237. Middle East Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 238. Africa Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 239. Africa Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 240. Africa Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 241. Africa Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 242. North America Test Phantoms Sales, by Country K Units (2014-2019)
  • Table 243. North America Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 244. North America Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 245. North America Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 246. North America Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 247. United States Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 248. United States Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 249. United States Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 250. United States Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 251. Canada Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 252. Canada Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 253. Canada Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 254. Canada Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 255. Mexico Test Phantoms Sales, by Type K Units (2014-2019)
  • Table 256. Mexico Test Phantoms Sales, by Application K Units (2014-2019)
  • Table 257. Mexico Test Phantoms Sales, by Patient Type K Units (2014-2019)
  • Table 258. Mexico Test Phantoms Sales, by Technologies K Units (2014-2019)
  • Table 259. Test Phantoms: by Type(USD/Units)
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Test Phantoms: by Type(USD Million)
  • Table 271. Test Phantoms CT Test Phantoms , by Region USD Million (2020-2025)
  • Table 272. Test Phantoms Mammography Test Phantoms , by Region USD Million (2020-2025)
  • Table 273. Test Phantoms Ultrasound Test Phantoms , by Region USD Million (2020-2025)
  • Table 274. Test Phantoms Radiation Oncology Test Phantoms , by Region USD Million (2020-2025)
  • Table 275. Test Phantoms MRI Test Phantoms , by Region USD Million (2020-2025)
  • Table 276. Test Phantoms Others , by Region USD Million (2020-2025)
  • Table 277. Test Phantoms: by Application(USD Million)
  • Table 278. Test Phantoms Research institute , by Region USD Million (2020-2025)
  • Table 279. Test Phantoms School , by Region USD Million (2020-2025)
  • Table 280. Test Phantoms Hospital , by Region USD Million (2020-2025)
  • Table 281. Test Phantoms Others , by Region USD Million (2020-2025)
  • Table 282. Test Phantoms: by Patient Type(USD Million)
  • Table 283. Test Phantoms Adult , by Region USD Million (2020-2025)
  • Table 284. Test Phantoms Pediatric , by Region USD Million (2020-2025)
  • Table 285. Test Phantoms: by Technologies(USD Million)
  • Table 286. Test Phantoms Radioactive spheres , by Region USD Million (2020-2025)
  • Table 287. Test Phantoms Radiography , by Region USD Million (2020-2025)
  • Table 288. Test Phantoms MRI versions , by Region USD Million (2020-2025)
  • Table 289. Test Phantoms Others , by Region USD Million (2020-2025)
  • Table 290. South America Test Phantoms, by Country USD Million (2020-2025)
  • Table 291. South America Test Phantoms, by Type USD Million (2020-2025)
  • Table 292. South America Test Phantoms, by Application USD Million (2020-2025)
  • Table 293. South America Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 294. South America Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 295. Brazil Test Phantoms, by Type USD Million (2020-2025)
  • Table 296. Brazil Test Phantoms, by Application USD Million (2020-2025)
  • Table 297. Brazil Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 298. Brazil Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 299. Argentina Test Phantoms, by Type USD Million (2020-2025)
  • Table 300. Argentina Test Phantoms, by Application USD Million (2020-2025)
  • Table 301. Argentina Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 302. Argentina Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 303. Rest of South America Test Phantoms, by Type USD Million (2020-2025)
  • Table 304. Rest of South America Test Phantoms, by Application USD Million (2020-2025)
  • Table 305. Rest of South America Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 306. Rest of South America Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 307. Asia Pacific Test Phantoms, by Country USD Million (2020-2025)
  • Table 308. Asia Pacific Test Phantoms, by Type USD Million (2020-2025)
  • Table 309. Asia Pacific Test Phantoms, by Application USD Million (2020-2025)
  • Table 310. Asia Pacific Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 311. Asia Pacific Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 312. China Test Phantoms, by Type USD Million (2020-2025)
  • Table 313. China Test Phantoms, by Application USD Million (2020-2025)
  • Table 314. China Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 315. China Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 316. Japan Test Phantoms, by Type USD Million (2020-2025)
  • Table 317. Japan Test Phantoms, by Application USD Million (2020-2025)
  • Table 318. Japan Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 319. Japan Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 320. India Test Phantoms, by Type USD Million (2020-2025)
  • Table 321. India Test Phantoms, by Application USD Million (2020-2025)
  • Table 322. India Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 323. India Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 324. South Korea Test Phantoms, by Type USD Million (2020-2025)
  • Table 325. South Korea Test Phantoms, by Application USD Million (2020-2025)
  • Table 326. South Korea Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 327. South Korea Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 328. Taiwan Test Phantoms, by Type USD Million (2020-2025)
  • Table 329. Taiwan Test Phantoms, by Application USD Million (2020-2025)
  • Table 330. Taiwan Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 331. Taiwan Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 332. Australia Test Phantoms, by Type USD Million (2020-2025)
  • Table 333. Australia Test Phantoms, by Application USD Million (2020-2025)
  • Table 334. Australia Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 335. Australia Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 336. Rest of Asia-Pacific Test Phantoms, by Type USD Million (2020-2025)
  • Table 337. Rest of Asia-Pacific Test Phantoms, by Application USD Million (2020-2025)
  • Table 338. Rest of Asia-Pacific Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 339. Rest of Asia-Pacific Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 340. Europe Test Phantoms, by Country USD Million (2020-2025)
  • Table 341. Europe Test Phantoms, by Type USD Million (2020-2025)
  • Table 342. Europe Test Phantoms, by Application USD Million (2020-2025)
  • Table 343. Europe Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 344. Europe Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 345. Germany Test Phantoms, by Type USD Million (2020-2025)
  • Table 346. Germany Test Phantoms, by Application USD Million (2020-2025)
  • Table 347. Germany Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 348. Germany Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 349. France Test Phantoms, by Type USD Million (2020-2025)
  • Table 350. France Test Phantoms, by Application USD Million (2020-2025)
  • Table 351. France Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 352. France Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 353. Italy Test Phantoms, by Type USD Million (2020-2025)
  • Table 354. Italy Test Phantoms, by Application USD Million (2020-2025)
  • Table 355. Italy Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 356. Italy Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 357. United Kingdom Test Phantoms, by Type USD Million (2020-2025)
  • Table 358. United Kingdom Test Phantoms, by Application USD Million (2020-2025)
  • Table 359. United Kingdom Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 360. United Kingdom Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 361. Netherlands Test Phantoms, by Type USD Million (2020-2025)
  • Table 362. Netherlands Test Phantoms, by Application USD Million (2020-2025)
  • Table 363. Netherlands Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 364. Netherlands Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 365. Rest of Europe Test Phantoms, by Type USD Million (2020-2025)
  • Table 366. Rest of Europe Test Phantoms, by Application USD Million (2020-2025)
  • Table 367. Rest of Europe Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 368. Rest of Europe Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 369. MEA Test Phantoms, by Country USD Million (2020-2025)
  • Table 370. MEA Test Phantoms, by Type USD Million (2020-2025)
  • Table 371. MEA Test Phantoms, by Application USD Million (2020-2025)
  • Table 372. MEA Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 373. MEA Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 374. Middle East Test Phantoms, by Type USD Million (2020-2025)
  • Table 375. Middle East Test Phantoms, by Application USD Million (2020-2025)
  • Table 376. Middle East Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 377. Middle East Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 378. Africa Test Phantoms, by Type USD Million (2020-2025)
  • Table 379. Africa Test Phantoms, by Application USD Million (2020-2025)
  • Table 380. Africa Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 381. Africa Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 382. North America Test Phantoms, by Country USD Million (2020-2025)
  • Table 383. North America Test Phantoms, by Type USD Million (2020-2025)
  • Table 384. North America Test Phantoms, by Application USD Million (2020-2025)
  • Table 385. North America Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 386. North America Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 387. United States Test Phantoms, by Type USD Million (2020-2025)
  • Table 388. United States Test Phantoms, by Application USD Million (2020-2025)
  • Table 389. United States Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 390. United States Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 391. Canada Test Phantoms, by Type USD Million (2020-2025)
  • Table 392. Canada Test Phantoms, by Application USD Million (2020-2025)
  • Table 393. Canada Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 394. Canada Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 395. Mexico Test Phantoms, by Type USD Million (2020-2025)
  • Table 396. Mexico Test Phantoms, by Application USD Million (2020-2025)
  • Table 397. Mexico Test Phantoms, by Patient Type USD Million (2020-2025)
  • Table 398. Mexico Test Phantoms, by Technologies USD Million (2020-2025)
  • Table 399. Test Phantoms Sales: by Type(K Units)
  • Table 400. Test Phantoms Sales CT Test Phantoms , by Region K Units (2020-2025)
  • Table 401. Test Phantoms Sales Mammography Test Phantoms , by Region K Units (2020-2025)
  • Table 402. Test Phantoms Sales Ultrasound Test Phantoms , by Region K Units (2020-2025)
  • Table 403. Test Phantoms Sales Radiation Oncology Test Phantoms , by Region K Units (2020-2025)
  • Table 404. Test Phantoms Sales MRI Test Phantoms , by Region K Units (2020-2025)
  • Table 405. Test Phantoms Sales Others , by Region K Units (2020-2025)
  • Table 406. Test Phantoms Sales: by Application(K Units)
  • Table 407. Test Phantoms Sales Research institute , by Region K Units (2020-2025)
  • Table 408. Test Phantoms Sales School , by Region K Units (2020-2025)
  • Table 409. Test Phantoms Sales Hospital , by Region K Units (2020-2025)
  • Table 410. Test Phantoms Sales Others , by Region K Units (2020-2025)
  • Table 411. Test Phantoms Sales: by Patient Type(K Units)
  • Table 412. Test Phantoms Sales Adult , by Region K Units (2020-2025)
  • Table 413. Test Phantoms Sales Pediatric , by Region K Units (2020-2025)
  • Table 414. Test Phantoms Sales: by Technologies(K Units)
  • Table 415. Test Phantoms Sales Radioactive spheres , by Region K Units (2020-2025)
  • Table 416. Test Phantoms Sales Radiography , by Region K Units (2020-2025)
  • Table 417. Test Phantoms Sales MRI versions , by Region K Units (2020-2025)
  • Table 418. Test Phantoms Sales Others , by Region K Units (2020-2025)
  • Table 419. South America Test Phantoms Sales, by Country K Units (2020-2025)
  • Table 420. South America Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 421. South America Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 422. South America Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 423. South America Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 424. Brazil Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 425. Brazil Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 426. Brazil Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 427. Brazil Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 428. Argentina Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 429. Argentina Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 430. Argentina Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 431. Argentina Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 432. Rest of South America Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 433. Rest of South America Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 434. Rest of South America Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 435. Rest of South America Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 436. Asia Pacific Test Phantoms Sales, by Country K Units (2020-2025)
  • Table 437. Asia Pacific Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 438. Asia Pacific Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 439. Asia Pacific Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 440. Asia Pacific Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 441. China Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 442. China Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 443. China Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 444. China Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 445. Japan Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 446. Japan Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 447. Japan Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 448. Japan Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 449. India Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 450. India Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 451. India Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 452. India Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 453. South Korea Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 454. South Korea Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 455. South Korea Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 456. South Korea Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 457. Taiwan Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 458. Taiwan Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 459. Taiwan Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 460. Taiwan Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 461. Australia Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 462. Australia Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 463. Australia Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 464. Australia Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 465. Rest of Asia-Pacific Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 466. Rest of Asia-Pacific Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 467. Rest of Asia-Pacific Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 468. Rest of Asia-Pacific Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 469. Europe Test Phantoms Sales, by Country K Units (2020-2025)
  • Table 470. Europe Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 471. Europe Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 472. Europe Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 473. Europe Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 474. Germany Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 475. Germany Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 476. Germany Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 477. Germany Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 478. France Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 479. France Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 480. France Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 481. France Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 482. Italy Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 483. Italy Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 484. Italy Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 485. Italy Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 486. United Kingdom Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 487. United Kingdom Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 488. United Kingdom Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 489. United Kingdom Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 490. Netherlands Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 491. Netherlands Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 492. Netherlands Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 493. Netherlands Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 494. Rest of Europe Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 495. Rest of Europe Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 496. Rest of Europe Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 497. Rest of Europe Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 498. MEA Test Phantoms Sales, by Country K Units (2020-2025)
  • Table 499. MEA Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 500. MEA Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 501. MEA Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 502. MEA Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 503. Middle East Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 504. Middle East Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 505. Middle East Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 506. Middle East Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 507. Africa Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 508. Africa Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 509. Africa Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 510. Africa Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 511. North America Test Phantoms Sales, by Country K Units (2020-2025)
  • Table 512. North America Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 513. North America Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 514. North America Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 515. North America Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 516. United States Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 517. United States Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 518. United States Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 519. United States Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 520. Canada Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 521. Canada Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 522. Canada Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 523. Canada Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 524. Mexico Test Phantoms Sales, by Type K Units (2020-2025)
  • Table 525. Mexico Test Phantoms Sales, by Application K Units (2020-2025)
  • Table 526. Mexico Test Phantoms Sales, by Patient Type K Units (2020-2025)
  • Table 527. Mexico Test Phantoms Sales, by Technologies K Units (2020-2025)
  • Table 528. Test Phantoms: by Type(USD/Units)
  • Table 529. Research Programs/Design for This Report
  • Table 530. Key Data Information from Secondary Sources
  • Table 531. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Test Phantoms: by Type USD Million (2014-2019)
  • Figure 5. Global Test Phantoms: by Application USD Million (2014-2019)
  • Figure 6. Global Test Phantoms: by Patient Type USD Million (2014-2019)
  • Figure 7. Global Test Phantoms: by Technologies USD Million (2014-2019)
  • Figure 8. South America Test Phantoms Share (%), by Country
  • Figure 9. Asia Pacific Test Phantoms Share (%), by Country
  • Figure 10. Europe Test Phantoms Share (%), by Country
  • Figure 11. MEA Test Phantoms Share (%), by Country
  • Figure 12. North America Test Phantoms Share (%), by Country
  • Figure 13. Global Test Phantoms: by Type K Units (2014-2019)
  • Figure 14. Global Test Phantoms: by Application K Units (2014-2019)
  • Figure 15. Global Test Phantoms: by Patient Type K Units (2014-2019)
  • Figure 16. Global Test Phantoms: by Technologies K Units (2014-2019)
  • Figure 17. South America Test Phantoms Share (%), by Country
  • Figure 18. Asia Pacific Test Phantoms Share (%), by Country
  • Figure 19. Europe Test Phantoms Share (%), by Country
  • Figure 20. MEA Test Phantoms Share (%), by Country
  • Figure 21. North America Test Phantoms Share (%), by Country
  • Figure 22. Global Test Phantoms: by Type USD/Units (2014-2019)
  • Figure 23. Global Test Phantoms share by Players 2019 (%)
  • Figure 24. Global Test Phantoms share by Players (Top 3) 2019(%)
  • Figure 25. Global Test Phantoms share by Players (Top 5) 2019(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Gammex (United States) Revenue, Net Income and Gross profit
  • Figure 28. Gammex (United States) Revenue: by Geography 2019
  • Figure 29. Fluke (United States) Revenue, Net Income and Gross profit
  • Figure 30. Fluke (United States) Revenue: by Geography 2019
  • Figure 31. Standard Imaging (United States) Revenue, Net Income and Gross profit
  • Figure 32. Standard Imaging (United States) Revenue: by Geography 2019
  • Figure 33. Biodex Medical Systems (United States) Revenue, Net Income and Gross profit
  • Figure 34. Biodex Medical Systems (United States) Revenue: by Geography 2019
  • Figure 35. RaySafe (Sweden) Revenue, Net Income and Gross profit
  • Figure 36. RaySafe (Sweden) Revenue: by Geography 2019
  • Figure 37. Capintec (United States) Revenue, Net Income and Gross profit
  • Figure 38. Capintec (United States) Revenue: by Geography 2019
  • Figure 39. Pro-Project (Poland) Revenue, Net Income and Gross profit
  • Figure 40. Pro-Project (Poland) Revenue: by Geography 2019
  • Figure 41. The Phantom Laboratory (United States) Revenue, Net Income and Gross profit
  • Figure 42. The Phantom Laboratory (United States) Revenue: by Geography 2019
  • Figure 43. Radiology Support Devices (United States) Revenue, Net Income and Gross profit
  • Figure 44. Radiology Support Devices (United States) Revenue: by Geography 2019
  • Figure 45. Modus Medical Devices (Canada) Revenue, Net Income and Gross profit
  • Figure 46. Modus Medical Devices (Canada) Revenue: by Geography 2019
  • Figure 47. Global Test Phantoms: by Type USD Million (2020-2025)
  • Figure 48. Global Test Phantoms: by Application USD Million (2020-2025)
  • Figure 49. Global Test Phantoms: by Patient Type USD Million (2020-2025)
  • Figure 50. Global Test Phantoms: by Technologies USD Million (2020-2025)
  • Figure 51. South America Test Phantoms Share (%), by Country
  • Figure 52. Asia Pacific Test Phantoms Share (%), by Country
  • Figure 53. Europe Test Phantoms Share (%), by Country
  • Figure 54. MEA Test Phantoms Share (%), by Country
  • Figure 55. North America Test Phantoms Share (%), by Country
  • Figure 56. Global Test Phantoms: by Type K Units (2020-2025)
  • Figure 57. Global Test Phantoms: by Application K Units (2020-2025)
  • Figure 58. Global Test Phantoms: by Patient Type K Units (2020-2025)
  • Figure 59. Global Test Phantoms: by Technologies K Units (2020-2025)
  • Figure 60. South America Test Phantoms Share (%), by Country
  • Figure 61. Asia Pacific Test Phantoms Share (%), by Country
  • Figure 62. Europe Test Phantoms Share (%), by Country
  • Figure 63. MEA Test Phantoms Share (%), by Country
  • Figure 64. North America Test Phantoms Share (%), by Country
  • Figure 65. Global Test Phantoms: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • Gammex (United States)
  • Fluke (United States)
  • Standard Imaging (United States)
  • Biodex Medical Systems (United States)
  • RaySafe (Sweden)
  • Capintec (United States)
  • Pro-Project (Poland)
  • The Phantom Laboratory (United States)
  • Radiology Support Devices (United States)
  • Modus Medical Devices (Canada)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation